The present invention uses a compound represented by general formula (II) or a pharmacologically acceptable salt thereof as a P2X4 receptor antagonist. (In the formula R11 and R12 each represents a hydrogen atom an alkyl group having 1 8 carbon atoms or the like R13 represents a hydrogen atom an alkyl group having 1 8 carbon atoms or the like R14 represents an alkoxy group having 1 8 carbon atoms a hydroxyl group a cyano group an optionally substituted heterocyclic group or the like and AA represents a naphthalene ring or the like.)
